{"id":9997,"date":"2026-01-05T06:41:01","date_gmt":"2026-01-05T12:41:01","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9997"},"modified":"2026-02-24T06:41:37","modified_gmt":"2026-02-24T12:41:37","slug":"nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/","title":{"rendered":"Nanoscope Therapeutics obtiene una nueva patente estadounidense que cubre su plataforma patentada de opsinas multicaracter\u00edsticas para la restauraci\u00f3n de la visi\u00f3n."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a07 de enero de 2026<\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 que la Oficina de Patentes y Marcas de los Estados Unidos (USPTO) ha otorgado\u00a0Patente estadounidense n.\u00b0 12459977<\/a>, reconociendo la empresa\u00a0Opsina multicaracter\u00edstica (MCO)<\/b>\u00a0Plataforma tecnol\u00f3gica como una opsina sint\u00e9tica novedosa e innovadora para la modulaci\u00f3n optogen\u00e9tica.<\/p>

La patente recientemente emitida proporciona una amplia protecci\u00f3n para los m\u00e9todos de uso de la plataforma MCO para restaurar la visi\u00f3n en pacientes que han perdido fotorreceptores debido a enfermedades degenerativas de la retina, como\u00a0retinitis pigmentosa<\/b>, enfermedad de Stargardt y atrofia geogr\u00e1fica<\/b>.<\/p>

Al otorgar la patente, la USPTO reconoci\u00f3 los atributos distintivos de la plataforma MCO de Nanoscope, que la diferencian de otros enfoques optogen\u00e9ticos a trav\u00e9s de su\u00a0Amplia sensibilidad espectral, cin\u00e9tica r\u00e1pida y capacidad de funcionar mediante activaci\u00f3n por luz ambiental.<\/b>\u2014eliminando la necesidad de dispositivos externos de amplificaci\u00f3n de luz.<\/p>

La patente extiende la protecci\u00f3n de la propiedad intelectual en los Estados Unidos a trav\u00e9s de\u00a02039<\/b>, con la posibilidad de una extensi\u00f3n adicional del plazo de la patente tras la aprobaci\u00f3n por la FDA de productos terap\u00e9uticos basados en la tecnolog\u00eda. Nanoscope tambi\u00e9n ha asegurado\u00a0Patentes correspondientes en Australia y Jap\u00f3n, con patentes pendientes en China y la UE.<\/b>, reforzando as\u00ed su posici\u00f3n de liderazgo mundial en propiedad intelectual en optogen\u00e9tica y respaldando la exclusividad comercial a largo plazo en los principales mercados.<\/p>

\u201cEsta patente representa m\u00e1s que un hito incremental en materia de propiedad intelectual: refuerza el valor estrat\u00e9gico de la plataforma MCO como una tecnolog\u00eda duradera y pionera con un amplio potencial cl\u00ednico y comercial\u201d, afirm\u00f3.\u00a0Sulagna Bhattacharya, directora ejecutiva de Nanoscope Therapeutics.<\/a>\u00a0\u201cEsto fortalece la base de nuestra cartera de productos al extender la exclusividad de mercado, mejorar las barreras competitivas y respaldar m\u00faltiples indicaciones futuras basadas en una plataforma optogen\u00e9tica \u00fanica y escalable.\u201d<\/p>

La concesi\u00f3n de esta patente de continuaci\u00f3n parcial subraya a\u00fan m\u00e1s el potencial de la plataforma MCO para brindar un beneficio terap\u00e9utico significativo a los pacientes que sufren una p\u00e9rdida grave de la visi\u00f3n, lo que respalda la misi\u00f3n de Nanoscope de devolver la vista a millones de personas afectadas por enfermedades degenerativas de la retina para las que actualmente no existen tratamientos aprobados.<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0A principios de 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a principios de 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Jan. 7, 2026\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, announced that the U.S. Patent and Trademark Office (USPTO) has granted\u00a0U.S. Patent No. 12459977, recognizing the company\u2019s\u00a0Multi-Characteristic Opsin (MCO)\u00a0technology platform as a novel and innovative […]<\/p>\n","protected":false},"author":6,"featured_media":10006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:41:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:41:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration\",\"datePublished\":\"2026-01-05T12:41:01+00:00\",\"dateModified\":\"2026-02-24T12:41:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_26_LI_USPatent_FINAL.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/\",\"name\":\"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_26_LI_USPatent_FINAL.jpg\",\"datePublished\":\"2026-01-05T12:41:01+00:00\",\"dateModified\":\"2026-02-24T12:41:37+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_26_LI_USPatent_FINAL.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_26_LI_USPatent_FINAL.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics obtiene una nueva patente estadounidense que cubre su plataforma patentada de opsina multicaracter\u00edstica para la restauraci\u00f3n de la visi\u00f3n - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-01-05T12:41:01+00:00","article_modified_time":"2026-02-24T12:41:37+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration","datePublished":"2026-01-05T12:41:01+00:00","dateModified":"2026-02-24T12:41:37+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/"},"wordCount":586,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_26_LI_USPatent_FINAL.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/","url":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/","name":"Nanoscope Therapeutics obtiene una nueva patente estadounidense que cubre su plataforma patentada de opsina multicaracter\u00edstica para la restauraci\u00f3n de la visi\u00f3n - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_26_LI_USPatent_FINAL.jpg","datePublished":"2026-01-05T12:41:01+00:00","dateModified":"2026-02-24T12:41:37+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_26_LI_USPatent_FINAL.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_26_LI_USPatent_FINAL.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-granted-new-u-s-patent-covering-its-proprietary-multi-characteristic-opsin-platform-for-vision-restoration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9997"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9997\/revisions"}],"predecessor-version":[{"id":10012,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9997\/revisions\/10012"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10006"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}